Prestige Consumer Healthcare Inc. (NYSE:PBH) Given Consensus Rating of “Hold” by Analysts

Prestige Consumer Healthcare Inc. (NYSE:PBH) has been assigned a consensus recommendation of “Hold” from the six brokerages that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $70.75.

PBH has been the subject of a number of research analyst reports. Canaccord Genuity Group lowered their price target on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating for the company in a report on Friday, May 15th. Oppenheimer lowered shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a report on Thursday, May 14th. Weiss Ratings cut shares of Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Thursday, June 25th. Finally, Zacks Research raised shares of Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research note on Monday, August 10th.

Prestige Consumer Healthcare Trading Up 2.1%

PBH opened at $52.85 on Wednesday. The stock has a market capitalization of $2.50 billion, a PE ratio of 14.80, a P/E/G ratio of 1.62 and a beta of 0.33. Prestige Consumer Healthcare has a one year low of $42.62 and a one year high of $71.07. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.99 and a current ratio of 3.23. The business’s 50 day moving average price is $50.48 and its 200 day moving average price is $54.35.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, August 6th. The company reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.89 by $0.09. Prestige Consumer Healthcare had a return on equity of 11.39% and a net margin of 15.57%.The company had revenue of $265.71 million during the quarter, compared to analysts’ expectations of $253.02 million. During the same quarter last year, the firm earned $0.90 earnings per share. The firm’s quarterly revenue was up 6.5% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.550-4.650 EPS. As a group, equities research analysts expect that Prestige Consumer Healthcare will post 4.56 EPS for the current year.

Hedge Funds Weigh In On Prestige Consumer Healthcare

Hedge funds have recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in Prestige Consumer Healthcare in the second quarter valued at approximately $370,187,000. California State Teachers Retirement System lifted its stake in Prestige Consumer Healthcare by 4,490.7% during the second quarter. California State Teachers Retirement System now owns 2,630,954 shares of the company’s stock worth $124,365,000 after purchasing an additional 2,573,644 shares in the last quarter. Rice Hall James & Associates LLC purchased a new position in shares of Prestige Consumer Healthcare during the second quarter worth $32,602,000. The Manufacturers Life Insurance Company purchased a new position in shares of Prestige Consumer Healthcare during the second quarter worth $31,135,000. Finally, Norges Bank acquired a new stake in shares of Prestige Consumer Healthcare in the fourth quarter valued at $36,954,000. Hedge funds and other institutional investors own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).